ICON looks priced for recovery: a durable global CRO with strong cash flow and backlog, temporarily discounted by accounting remediation, softer guidance, and governance concerns.
Overview
ICON is a leading global CRO serving pharma, biotech, medical device, government, and public-health customers across 106 locations in 55 countries. Revenue is geographically diversified, led by Europe and the U.S., and generated through long-term clinical development contracts. Its services span early-phase development, global Phase II-IV trials, decentralized trials, labs, cardiac safety, and functional outsourcing. Sponsors value ICON’s scale, therapeutic depth, 1,200+ site network, and trial-management technology, making it a critical infrastructure provider in the global drug-development ecosystem.